

Anti-CD8B hIgG1 Antibody(xhCD8v12)

Product information

GM-88302AB-10	10 µg
GM-88302AB-100	100 µg
GM-88302AB-1000	1 mg

Antibody Information

Species Reactivity	Human
Clone	xhCD8v12
Source/Isotype	Human IgG1,Kappa
Application	Flow Cytometry
Target	Detects CD8B
Gene	CD8B
Other Names	CD8B1, CD8beta, LEU2, LY3, LYT3, Ly-3, P37
Gene ID	926 (Human)
Background	CD8B gene encodes the CD8β chain, an important component of the CD8 co-receptor that, together with CD8α, forms a cell-surface dimer. It aids CD8+ T cells in recognizing antigenic peptides presented by MHC I, enhancing cytotoxic responses, and it participates in signaling, proliferation, and the formation of memory T cells. Research focuses on expression changes and functional regulation of CD8β in tumor immunity, autoimmunity, and immune regulation, exploring strategies to boost anti-tumor immunity or mitigate autoimmune responses by modulating the CD8β pathway. In terms of antibody applications, the core approaches include monoclonal antibodies and bispecific antibodies against CD8β for cell sorting and functional blockade or enhancement, potential applications of antibody-drug conjugates and immunotherapy combinations, and marking/detection for diagnostic and immunophenotyping analyses. In cell therapy, CD8β antibodies can also be used for sorting, labeling, or modulating humanized T cells. Experimental design should pay attention to antibody specificity, epitope targeting, cross-species reactivity, and the impact of sample fixation state on different applications, while integrating multi-omics data to comprehensively interpret the function and clinical potential of CD8β.
Storage	Store at 2-8°C short term (1-2 weeks).Store at ≤ -20°C long term. Avoid repeated freeze-thaw.
Formulation	Phosphate-buffered solution, pH 7.2-7.4.
Endotoxin	< 1 EU/mg, determined by LAL gel clotting assay

Version:3.1

Data Examples

Flow cytometry

H_CD8A CD8B HEK-293 Cell Line (Catalog # GM-C41739) was stained with Anti-CD8B hIgG1 Antibody(xhCD8v12) (Catalog # GM-88302AB) or isotype control antibody, followed by anti-Human IgG APC-conjugated Secondary Antibody.




Fig. FACS